


Strategic Partnership with 1315 Capital

17 March 2025



Today's Announcement

Addition of a diversifying and growth-oriented Partner Firm, further broadening NGI's exposure to Private Equity

Strategic Minority Stake in an Industry Leading Healthcare Investment Firm



Key Terms

- NGI will acquire a 23.5% strategic equity stake in 1315 Capital, including a minority interest in certain carried interest for a total maximum consideration of USD 70.5 million, of which USD 27.5 million is deferred and subject to performance criteria
- The minority investment from NGI will have no impact on the day-to-day management or operations of 1315 Capital and the firm's investment and decision-making processes will also remain unchanged
- Various minority protections agreed with a focus on a strong alignment of interests

Compelling Transaction Rationale

- ✓ Addition of an established firm with proven industry expertise
- ✓ Long-duration AUM and high-quality earnings with strong growth outlook
- ✓ High-quality institutional investor base and strong capital formation pipeline
- ✓ Expected to generate attractive cash flow to NGI over time as future funds are raised and existing portfolio is realized

- ✓ Attractive risk/return strategy targeting a highly fragmented and less efficient part of the private market
- ✓ Focus on established but growing private healthcare companies in sub-sectors with limited exposure to key industry risk (e.g. reimbursement, regulatory or clinical risks)
- ✓ Large, well capitalized universe of acquirers for 1315 Capital's portfolio companies in a sector generally more enduring and less cyclical, with tailwinds across target subsectors and investment themes

Transaction consideration will be funded out of existing financial resources



Overview of 1315 Capital



1315 Capital invests in high-quality healthcare teams and companies, primarily based in the U.S.

Firm Highlights


Established 2014

Headquarters Philadelphia, USA

AUM USD \$1 billion¹

Current Team Size² 20

Existing Portfolio Companies³ 30



Investment Approach

Investment Leadership

The 1315 Capital investment team combines financial and business development expertise with deep industry knowledge to support the growth of their portfolio companies.

Operating Teams

1315 Capital employs an Operating Team model to navigate diligence, drive decisions, and seeks to achieve premium exits.

Tangible Engagement


1315 Capital has a large network that it leverages for management talent, advisors, deal sourcing, diligence, and board roles.

Targets USD 10 million to USD 40 million investments in commercial, revenue generating healthcare businesses that have the potential to scale to USD 50 million to USD 150 million of revenue, a level 1315 Capital believes is highly attractive for acquisition or to access the public markets

1315 Capital provides expansion and growth capital to commercial-stage medtech & pharma outsourcing, healthcare services, medical technology, and health & wellness companies⁴



^{2.} Includes Operating Team Members





^{3.} Excludes portfolio company investments that have not been publicly announced.



1315 Capital Team

Cohesive and experienced team of 20 professionals¹ who combine financial and business development expertise with deep industry knowledge

Adele C. Oliva
Founding Partner



Adele C. Oliva has been a healthcare investor for over 20 years and founded 1315 Capital in 2014 to establish an investment firm focused on healthcare growth equity and buyouts. The firm has since raised multiple funds and has over \$1 billion under management. Prior to founding 1315 Capital, Adele had been recruited to Quaker Partners in 2007 to expand their growth stage investing practice, and prior to Quaker, she was Co-Head of US Healthcare at Apax Partners, where she spent a decade in both Silicon Valley and Manhattan.

Prior to entering private equity as a Kauffman Fellow, Adele held roles at CoreStates and Baxter Healthcare.

Adele received a BSc from St. Joseph's University and an MBA from Cornell University, where she was awarded the Albert Fried Fellowship.

Michael KobyFounding Partner



Michael Koby co-founded 1315 Capital in 2014, after spending his entire career as a healthcare investor and operator, including experience with more than 25 growth equity investments. Prior to founding 1315 Capital, Michael was a Managing Director at Palm Ventures, a private-equity focused family office where he led all healthcare investing.

Before Palm Ventures, Michael spent over a decade as an investor, including before and after business school, at Galen Partners, a healthcare growth equity investment firm. He also held business development roles at Novoste Corporation and Medtronic, Inc.

Michael started his career as a healthcare investment banking analyst at Dillon, Read & Co. Michael received a BSc from Cornell University and an MBA in Healthcare Management from The Wharton School.

The 1315 Capital team has been investing exclusively in expansion and growth stage healthcare companies their entire careers, with proven results through multiple market cycles





New Partner Firm Highlights

Leading healthcare focused private equity firm dedicated to investing in high quality, commercial-stage healthcare companies, predominately in the US

Experienced and driven team with strong culture

Deep and diverse investment expertise across attractive healthcare sectors

Proven track record of delivering strong risk-adjusted returns through differentiated and scalable investment process

Differentiated deal sourcing capabilities supported by deep industry expertise and extensive proprietary relationships

Demonstrated history of successful capital raising with long standing client relationships

Strong outlook for growth across investment offerings, client type and geographies



1315

Compelling Rationale and Strong Outlook

Executing on our growth strategy focused on long term shareholder value creation

NGI Key Rationale



- ✓ Leadership position in an attractive sector of the economy and private equity asset class
- ✓ Scaled, yet growing, business with resources in place to execute on growth plan and deliver continued strong investment results
- ✓ Diversification benefit to NGI through investment strategy and earnings profile
- ✓ Partnership oriented team with a proven focus on building a lasting franchise





Important Notices & Disclaimer

This presentation has been prepared by Navigator Global Investments Limited (NGI) and provides information regarding NGI and its activities current as at 17 March 2025. It is in summary form and is not necessarily complete. It should be read in conjunction with NGI's 30 June 2024 Annual Financial Report, 31 December 2024 Interim Financial Report and other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at www.asx.com.au.

By accessing this presentation you acknowledge and agree to the terms set out in this "Important Notice".

This presentation is of a general nature only and for information purposes only and should not be considered an offer, invitation or recommendation to acquire shares or any other financial products. Reliance should not be placed on information or opinions contained in this presentation and, subject only to any legal obligation to do so, NGI does not have any obligation to correct or update the content of this presentation. The information in this presentation remains subject to change without notice.

NO OFFER OF SECURITIES

Nothing in this presentation should be construed as either an offer or a solicitation of an offer to buy or sell securities in NGI in any jurisdiction or be treated or relied upon as a recommendation or advice by NGI. This presentation is for information purposes only and is not a prospectus, product disclosure statement or other offering document under Australian law or any other law (and will not be lodged with the Australian Securities and Investments Commission (ASIC) or any other foreign regulator). This presentation is not, and does not constitute, an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this presentation (including an electronic copy) in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

NOT FINANCIAL PRODUCT ADVICE

This presentation does not, and does not purport to, contain all information necessary to make an investment decision. Nothing in this presentation constitutes legal, financial, tax, accounting or other advice or any recommendation by NGI and will not form any part of any contract for the acquisition of Shares. The information in this presentation does not take into account the particular investment objectives, financial situation, taxation position or needs of any person. You should not rely on the presentation, and in all cases, you should conduct your own investigations and analysis of the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of NGI, and the contents of this presentation and seek legal, financial, tax and other professional advice.

INVESTMENT RISK

An investment in NGI shares is subject to investment and other known and unknown risks, some of which are beyond the control of NGI including possible loss of income and principal invested. NGI does not guarantee any particular rate of return or the performance of NGI, nor does it guarantee the repayment of capital from NGI or any particular tax treatment.

DISCLAIMER

While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty is made as to the accuracy, adequacy or reliability of any statements, estimates, opinions or any other information contained in this presentation. To the maximum extent permitted by law, the NGI Group, its directors, officers, employees, agents and any other person: expressly disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may be suffered through use or reliance on anything contained in or omitted from this presentation; disclaims any obligations or undertaking to release any updates or revision to the information in this presentation; and does not make any presentation or warranty, express or implied, as to the accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation or that this presentation contains all material information about NGI or its investment in 1315 Capital that a prospective investor may require in evaluating a possible investment in NGI or acquisition of shares in NGI, or likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward looking statement. The information in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation and particular needs.

FORWARD-LOOKING STATEMENTS

Certain statements in this presentation may constitute "forward-looking" statements. Forward Statements can be identified by the use of 'forward-looking' terminology, including, without limitation, the terms 'believes', 'estimates', 'artgets', 'projects', 'propose', 'goals', 'fargets', 'airngets', 'airnge

PAST PERFORMANCE

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon (and is not) and indication of future performance.

Nothing contained in this presentation, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future.

